TY - JOUR
T1 - Proteinase-activated receptor-2 activation induces uterine contractility in term pregnant rats that is not dependent on mast cell activation and cyclo-oxygenase products
AU - Maul, Holger
AU - Bytautiene, Egle
AU - Vedernikov, Yuri
AU - Garfield, Robert E.
AU - Saade, George R.
AU - Shah, Dinesh
N1 - Funding Information:
Supported by NIH grant No. R03-HD042713.
PY - 2003/6/1
Y1 - 2003/6/1
N2 - OBJECTIVES: This study was undertaken to evaluate the effect of proteinase-activated receptor-2 (PAR-2) activation on the contractility of uterine tissues from term pregnant rats and the role of mast cells and prostaglandins in such an effect. STUDY DESIGN: Uterine rings from pregnant (day 20-21) Sprague-Dawley rats were used for isometric tension recording in organ chamber experiments (Krebs solution, 5% carbon dioxide in air, 37°C, pH ∼7.4). Responses to the PAR-2 activating peptide SLIGRL (serine-leucine-isoleucine-glycine-arginine-leucine), and to the inactive reverse peptide LRGILS (leucine-arginine-glycine-isoleucine-leucine-serine) were determined after pretreatments with compound 48/80, cromolyn, S[+]-chlorpheniramine maleate, cimetidine, combinations of histamine (H) receptor antagonists with cromolyn or ibuprofen and compared with vehicle. RESULTS SLIGRL significantly augmented contractility of uterine tissues, and this response was not inhibited by compound 48/80, cromolyn, and ibuprofen, as well as by H1- and H2-receptor antagonists, alone or in combination with cromolyn. CONCLUSION: PAR-2 activation augments uterine contractility in tissues obtained from term pregnant rats, and this effect is independent of mast cell activation or cyclo-oxygenase pathway products.
AB - OBJECTIVES: This study was undertaken to evaluate the effect of proteinase-activated receptor-2 (PAR-2) activation on the contractility of uterine tissues from term pregnant rats and the role of mast cells and prostaglandins in such an effect. STUDY DESIGN: Uterine rings from pregnant (day 20-21) Sprague-Dawley rats were used for isometric tension recording in organ chamber experiments (Krebs solution, 5% carbon dioxide in air, 37°C, pH ∼7.4). Responses to the PAR-2 activating peptide SLIGRL (serine-leucine-isoleucine-glycine-arginine-leucine), and to the inactive reverse peptide LRGILS (leucine-arginine-glycine-isoleucine-leucine-serine) were determined after pretreatments with compound 48/80, cromolyn, S[+]-chlorpheniramine maleate, cimetidine, combinations of histamine (H) receptor antagonists with cromolyn or ibuprofen and compared with vehicle. RESULTS SLIGRL significantly augmented contractility of uterine tissues, and this response was not inhibited by compound 48/80, cromolyn, and ibuprofen, as well as by H1- and H2-receptor antagonists, alone or in combination with cromolyn. CONCLUSION: PAR-2 activation augments uterine contractility in tissues obtained from term pregnant rats, and this effect is independent of mast cell activation or cyclo-oxygenase pathway products.
KW - Histamine
KW - Mast cells
KW - Myometrium
KW - PAR-2
KW - Rat
UR - http://www.scopus.com/inward/record.url?scp=0038338609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038338609&partnerID=8YFLogxK
U2 - 10.1067/mob.2003.400
DO - 10.1067/mob.2003.400
M3 - Article
C2 - 12824984
AN - SCOPUS:0038338609
SN - 0002-9378
VL - 188
SP - 1498
EP - 1503
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 6
ER -